31May

Heat Biologics's allogeneic cellular vaccine in combination with nivolumab shown efficacy signals in phase I/II data

Tumor antigen expression and survival of patients with previously treated advanced non-small cell lung cancer (NSCLC) receiving viagenpumatucel-L (HS-110) plus nivolumab


Abstract No : 9546

Abstract Type : Poster Session

Indication : Non-Small Cell Lung Cancer

Intervention : VIagenpumatucel-L plus nivolumab

Company : Heat Biologics

Technology : Allogeneic cellular vaccine


Results:

Results: 47 pts were enrolled into Cohort A. ORR and clinical benefit rate (CR + PR + SD) were 21% and 43%, respectively, with a 17.2 month median duration of response. Median OS was 28.7 months (mos), with a median follow up of 15.7 mos. One and 2-year survival were 57% and 36%, respectively. A prespecified exploratory analysis of CTA expression level in baseline pt tumor tissue was performed. 50% of pts shared at least 8 of the 39 total antigens overexpressed by HS110. Although there was no difference in ORR between these groups, mOS was higher in pts with tumors that shared $ 8 antigens with HS-110 (not reached (NR) [95%CI: 10.3 mos, NR] vs 6.7 mos [95%CI: 1.4 mos, NR]), p = 0.028. Pts whose tumors expressed the ZNF492 antigen also had improved OS (NR [95%CI: 11.6 mos, NR] vs 7.2 mos [95%CI: 1.6 mos, NR]), p = 0.03. All pts experienced at least one adverse event (AE), and the most common AEs were fatigue (28%), arthralgia (19%) and cough (17%). There were 2 grade 5 AEs not related to treatment


Conclusion:

The combination of HS-110 and nivolumab appears safe and well tolerated. OS was improved in pts whose tumors express ≥ 8 shared antigens with HS110, as well as in those who specifically expressed ZNF492. Further exploration of antigen expression as a predictor for treatment outcome with HS110 plus nivolumab is ongoing.


Commentary:

Viagenpumatucel-L (HS-110) (an allogeneic cellular vaccine) plus nivolumab is well tolerated with a median overall survival (OS) of 28.7 months and this favourable benefits observed in both PD-L1 positive and PD-L1 negative patients.


Refer to Non Small Cell Lung Cancer Market report for detailed Insights.